ArticleInvestigative ophthalmology & visual science2026
Epstein-Barr Virus-Induced Upregulation of GPR183: A Potential Upstream Mechanism in IgG4-Related Ophthalmic Disease.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Immunoglobulin G4-related ophthalmic disease (IgG4-ROD) is the most common subtype of IgG4-related disease (IgG4-RD), yet its pathogenic mechanisms remain poorly understood. Ectopic germinal centers are a hallmark histopathological feature of IgG4-ROD, but the molecular drivers underlying their formation remain unclear. This study aimed to identify potential upstream triggers of IgG4-ROD and novel therapeutic targets. Methods: Fourteen patients with IgG4-ROD and 13 controls (9 with lacrimal gland prolapse and 4 with chronic dacryoadenitis) were enrolled. Lacrimal gland specimens were analyzed using bulk RNA sequencing (RNA-seq), multiplex immunofluorescence, flow cytometry, and quantitative real-time PCR (qPCR). Public bulk and single-cell RNA-seq datasets were further analyzed. Results: GPR183 was the only gene consistently upregulated across lacrimal gland, salivary gland, peripheral blood, and retroperitoneal fibrosis tissues from patients with IgG4-RD. GPR183 was broadly expressed across multiple immune cell populations in lacrimal glands. Multiplex immunofluorescence demonstrated prominent GPR183 expression within ectopic germinal centers, particularly in B-lymphocyte-rich regions. The qPCR revealed a significantly higher Epstein-Barr virus (EBV) positivity rate in IgG4-ROD lacrimal glands than in controls (85.7% vs. 15.4%, P < 0.001). EBV DNA copy number positively correlated with serum IgG4 levels (adjusted R² = 0.79, P < 0.01). EBV markers EBNA1 and LMP1 were co-expressed with GPR183. Single-cell RNA-seq showed that early EBV infection induced GPR183 expression in T and B lymphocytes and was associated with B-lymphocyte differentiation. Conclusions: Our findings suggest that EBV-induced GPR183 upregulation potentially promotes ectopic germinal center formation and contributes to the pathogenesis of IgG4-ROD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.